Keqin Xu1,2
Yujing Li
Emily G. Allen
Peng Jin- 1Department of Human Genetics, School of Medicine, Emory University, Atlanta, GA, United States
- 2Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
Non-coding repeat expansions, such as CGG, GGC, CUG, CCUG, and GGGGCC, have been shown to be involved in many human diseases, particularly neurological disorders. Of the diverse pathogenic mechanisms proposed in these neurodegenerative diseases, dysregulated RNA metabolism has emerged as an important contributor. Expanded repeat RNAs that form particular structures aggregate to form RNA foci, sequestering various RNA binding proteins and consequently altering RNA splicing, transport, and other downstream biological processes. One of these repeat expansion-associated diseases, fragile X-associated tremor/ataxia syndrome (FXTAS), is caused by a CGG repeat expansion in the 5’UTR region of the fragile X mental retardation 1 (FMR1) gene. Moreover, recent studies have revealed abnormal GGC repeat expansion within the 5’UTR region of the NOTCH2NLC gene in both essential tremor (ET) and neuronal intranuclear inclusion disease (NIID). These CGG repeat expansion-associated diseases share genetic, pathological, and clinical features. Identification of the similarities at the molecular level could lead to a better understanding of the disease mechanisms as well as developing novel therapeutic strategies. Here, we highlight our current understanding of the molecular pathogenesis of CGG repeat expansion-associated diseases and discuss potential therapeutic interventions for these neurological disorders.
Introduction
Microsatellite repeat expansions, also known as simple sequence repeats (SSR) or short tandem repeats (STR), are short repeat sequences consisting of 3–6 nucleotides that comprise around 3% of the human genome (Ellegren, 2004; Mirkin, 2007; Richard et al., 2008). They can occur in coding regions, intronic regions, 5’ and 3’ untranslated regions (UTRs), and intergenic regions (Toth et al., 2000; Payseur et al., 2011; Figure 1). The repeat length is also highly variable and can range from hundreds to a few thousand (Zhang and Ashizawa, 2017). Thus far, over 40 neurodegenerative diseases have been reported to be caused by the expansion of an unstable repeat sequences in the associated genes.
Figure 1. This image gives an overview of the repeat expansions seen in different diseases with the gene locations for each repeat.
Fragile X-associated tremor/ataxia syndrome (FXTAS) is one of these repeat expansion disorders characterized by a CGG or GGC repeat expansion (55–200 repeats) in the 5′ UTR of the Fragile X Mental Retardation 1 (FMR1) gene (Hagerman et al., 2001). Clinical features include progressive gait ataxia, intention tremor, cognitive decline, and Parkinsonism (Berry-Kravis et al., 2007). The carrier frequency of the CGG premutation is 1 in 813 males and 1 in 259 females in the general population, and it is estimated that 1 in 3,000 males from the general population will have a risk of developing FXTAS (Dombrowski et al., 2002; Jacquemont et al., 2004). In contrast to FXTAS, those carrying CGG repeats greater than 200 in the FMR1 gene can present with fragile X syndrome (FXS), another neurodegenerative disease that has different clinical features. The clinical manifestations of FXS include delayed development of speech and language, increased susceptibility to seizures, anxiety, and hyperactive behavior (Hagerman et al., 2017). Unlike FXTAS, the larger number of CGG repeats in FXS leads to DNA methylation and transcriptional gene silencing, resulting in the loss of fragile X mental retardation protein (FMRP).
In addition to fragile X-associated disorders, recent studies have advanced our understanding of CGG or GGC repeat expansions in neurodegenerative disease. A flurry of recent exciting studies have revealed that the expanded GGC repeat, located in the 5′ UTR of the NOTCH2NLC gene, is a causative genetic contributor to NOTCH2NLC-related repeat expansion disorders, including neuronal intranuclear inclusion disease (NIID), Alzheimer’s disease, Parkinson’s disease, essential tremor (ET), leukoencephalopathy, and frontotemporal dementia (Deng et al., 2019; Ishiura et al., 2019; Okubo et al., 2019; Sone et al., 2019; Tian et al., 2019; Jiao et al., 2020; Ma et al., 2020; Sun et al., 2020). Neuronal intranuclear inclusion disease (NIID) is a neurodegenerative disease characterized by the widely distributed eosinophilic hyaline intranuclear inclusions in the central nervous system and peripheral nervous system. Clinically, NIID presents with a broad spectrum of manifestations, including dementia, autonomic dysfunction, cerebellar ataxia, parkinsonism, and peripheral neuropathy (Sone et al., 2016). Aside from the presence of CGG/GGC repeat expansions that have been found in both NIID and FXTAS, they share some striking similarities on clinical characteristics (Gelpi et al., 2017; Lim et al., 2020). First, tremor and ataxia are the common clinical features in patients with NIID and FXTAS. Second, brain MRI showed the same change of T2-weighted hyperintensity areas in the middle cerebellar peduncles (MCP sign; Ishiura et al., 2019). Furthermore both have the hallmark feature of eosinophilic intranuclear inclusions in the brain and non-neuronal tissues (Haltia et al., 1984; Hunsaker et al., 2011; Sone et al., 2011). These shared characteristics suggest that these CGG repeat expansion-associated diseases may share a common pathologic mechanism due to the neuronal toxicity caused by CGG repeats. Therefore, a better understanding of the molecular pathogenesis of these diseases will facilitate further development of novel therapeutic strategies.
Because NIID and its related disorders have only drawn increased attention within the last 2 years, there has not been considerable research done to understand the mechanism of disease, let alone identification of potential therapies. Based on the similarities shared by these CGG/GCC repeat expansion disorders, using the existing knowledge of CGG repeat expansions in FXTAS could provide meaningful references. Based on FXTAS research, two major mechanisms have been proposed: RNA gain-of-function and repeat-associated non-AUG (RAN) translation (Jin et al., 2007; Sofola et al., 2007; Sellier et al., 2013; Todd et al., 2013). The presence of both toxic mRNA and an FMRpolyG peptide have been confirmed in human and animal models, and both may have an effect on disease pathogenesis. So far, there is not a consensus, but the current therapies are based on these two mechanisms. In this review article, we will outline the latest advances in the mechanisms of CGG repeat expansion-associated diseases, particularly FXTAS and NOTCH2NLC-related disorders, with a main focus on the development of therapeutic strategies.
Toxic Gain-of-Function Mechanism Caused By Expanded CGG Repeats
Repeat-containing RNAs with toxic gain-of-function generated from the repeat expansions in the non-coding regions of the gene(s) have been linked to diverse human diseases, including myotonic dystrophy type 1 (DM1), myotonic dystrophy type 2 (DM2), Spinocerebellar Ataxia Type 8 (SCA 8), and FXTAS (La Spada and Taylor, 2010; Todd and Paulson, 2010). The RNA toxicity mechanism depends on the repeat size, repeat location, the RNA-binding proteins that are sequestered by the repeat-containing RNAs, and their translated products. Theoretically, the expanded repeat RNA can form special structures and aggregates to form RNA foci. The repeat RNA within these foci will directly interact with repeat RNA-binding proteins (RBPs) and thereby sequestrating their normal function, which leads to downstream alterations, resulting in cellular toxicity.
Our current understanding of the CGG repeat RNA toxicity in FXTAS pathogenesis comes from multiple studies of human post-mortem tissues and experimental animal models. CGG-containing RNA levels are increased up to eight-fold while protein levels remain normal or slightly reduced in patients (Kenneson et al., 2001). To determine the gain-of-toxicity mechanism from the CGG repeats, a set of studies with Drosophila and mice showed deleterious neurodegeneration with the expression of expanded CGG repeats (Jin et al., 2003; Hukema et al., 2014). Further, studies of post-mortem FXTAS brains revealed the presence of CGG-containing transcripts in ubiquitinated nuclear inclusions. These findings strongly support the significance of CGG repeat RNA in a toxic gain-of-function mechanism.
The expanded CGG repeats can form a hairpin structure that creates excess binding sites for RBPs, sequestering them from interacting with other substrates, causing downstream biological effects and contributing to pathology. Various RBPs have been reported in human, fly and mouse FXTAS models, such as Pur-alpha (Pura), Heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNPA2/B1), Muscleblind Like Splicing Regulator 1 (MBNL1), SRC associated in mitosis of 68 kDa (Sam68), CUG-binding proteins (CUGBP1), Heterogeneous nuclear ribonuclearproteins (hnRNP G), and Drosha and DiGeorge syndrome critical region 8 complex (Drosha-DGCR8; Jin et al., 2007; Sofola et al., 2007; Sellier et al., 2010, 2013; Muslimov et al., 2011). Moreover, overexpression of most of these RBPs can suppress RNA toxicity and rescue the phenotype. For example, CGG repeats can sequestrate DGCR8 and DROSHA, which play an important role in microRNA biogenesis. Sequestration of DGCR8 and DROSHA by expanded CGG repeats expressed in cells lines and in human FXTAS brains could lead to a reduction of microRNAs generation. Studies have shown reduced neuronal cell viability in neuronal cells expressing CGG repeats; however, the overexpression of DGCR8 was able to rescue neuronal cell death (Sellier et al., 2013). Extending this RNA toxicity mechanism to other CGG/GGC repeat disorders like NIID, which contains a GGC repeat expansion in NOTCH2NLC gene, we could speculate that the GGC-containing transcripts may also exist in the ubiquitinated nuclear inclusions of NIID. Further, the GGC and CGG repeat RNAs could share the same secondary structures, recruiting similar RBPs into nuclear inclusions, preventing their normal functions in RNA localization and transport in neurons, and consequently leading to severe phenotypes.
In summary, the expression of the expanded CGG repeat transcripts significantly correlates with neurodegenerative phenotypes, although their contribution to the disease pathogenesis remains to be defined. Thus, further studies on repeat-containing RNA toxicity are needed to identify similarities and specificities for the various types of CGG repeat diseases.
Repeat-Associated Non-AUG (RAN) Translation
In addition to the RNA gain-of-function mechanism, a newly recognized mechanism of RAN translation has been proposed. In RAN translation, proteins are synthesized directly from the expanded repeats in the absence of the canonical AUG start codon (Zu et al., 2011). RAN translation has been detected in many repeat expansion disorders (e.g., Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (ALS-FTD) with expanded GGGGCC repeats, Spinocerebellar Ataxia Type 8 (SCA8) with CAG repeats, and FXTAS with CGG repeats (Zu et al., 2011; Sellier et al., 2013), suggesting an essential role of the shared RAN translation mechanism in disorders caused by various repeat expansion.
Using FXTAS as an example, researchers realized that previous findings of RNA toxicity mechanism alone could not fully account for the intranuclear inclusions in patients. In the FXTAS human brain, the large ubiquitin-positive aggregates are not only made of RBPs but rather of various proteins that do not interact directly with CGG-repeat mRNA (Greco et al., 2006; Iwahashi et al., 2006), which resemble the intranuclear inclusions in protein-mediated neurodegenerative disorders (Williams and Paulson, 2008). To understand this protein-mediated toxicity, significant effort has been made in the last decade. Abundant studies suggest that the CGG-repeat RNAs can be RAN translated into pathogenic polyglycine-containing proteins (FMRpolyG) that contain an expanded polyglycine stretch near the N-terminus and is directly linked to FXTAS. FMRpolyG, detected in the intranuclear inclusions, is a protein prone to aggregation. Expression of the FMRployG can alter the ubiquitin-proteasome system (UPS) in both cell and fly models (Boivin et al., 2018). Indeed, FMRpolyG has been confirmed to exist in FXTAS patient brains as well as fly and mouse FXTAS models (Todd et al., 2013). Furthermore, FMRpolyG has been directly linked to the CGG-repeat-associated toxicity in FXTAS mouse and Drosophila models. More specifically, FXTAS mice with expression of the 5′UTR of Fmr1 show neuronal inclusion formation, Purkinje cell loss, and locomotor deficits, while mice expressing CGG repeat RNA without FMRpolyG did not exhibit neurodegeneration as measured with behavioral tests. Notably, overexpression of lamina-associated polypeptide 2 beta (LAP2β), a nuclear membrane protein that co-precipitated with FMRpolyG, could rescue neuronal cell death caused by FMRpolyG (Sellier et al., 2017). These findings significantly support the contribution of RAN translation to the pathogenesis of FXTAS.
Given that NIID patients have a similar size of GGC repeats embedded in the 5′UTR, which also forms the hairpin RNA structure which could enhance translation initiation at the near-cognate codons located upstream of the repeats (Todd et al., 2013), it is logical to predict that RAN translation may occur in NIID as well. Furthermore, a defining signature of NIID is the intranuclear inclusions in patient tissues. Interestingly, the intranuclear inclusions in NIID patients partially resemble those of FXTAS, which are both ubiquitinated and immunoreactive for p62 (Mori et al., 2012), supporting our prediction that NIID and FXTAS could share overlapping mechanisms of neurodegeneration characterized by formation of the neural inclusions. Studies of the inclusion components have confirmed the presence of N-Ethylmaleimide Sensitive Factor (NSF), Syntaxin-binding protein 1 (Unc18–1), Heat shock protein 90 (HSP90), and Dynamin-1-like protein (DNM1L) in intranuclear inclusions from NIID human brain tissue (Pountney et al., 2008). Based on the known inclusion components in FXTAS, it will be interesting to determine whether the mutant protein caused by RAN translation is also present in the intranuclear inclusions of NIID.
Thus far, much of what we knew comes from study of FXTAS models, motivating us to infer that other CGG repeat disorders may also undergo RAN translation, which contributes to neurodegeneration. However, whether CGG RNA toxicity or RAN translation of CGG repeats might contribute to pathogenicity in CGG repeat disorders other than FXTAS is not yet known, as the pathology of these repeat disorders at the molecular level are far more complex than originally thought.
Therapeutic Development
Currently, no therapies are sufficient to cure CGG expansion disorders, and current clinical treatments are only able to relieve symptoms of patients. The progress in research into disease mechanisms serves as a bottleneck to facilitate the development of preventive and therapeutic interventions. Given that mutant RNA containing expanded CGG repeats can be pathogenic by sequestering RBPs as well as being translated into toxic proteins, several potential therapeutic approaches could be developed via targeting at the DNA, RNA, and protein levels. Specifically, blocking generation of or enhancing degradation of the repeat-containing RNAs, inhibiting the RNA-protein interactions, and reducing the toxic protein aggregation could open a new avenue for development of therapeutic strategies for FXTAS, NIID, and other disorders caused by CGG/GGC repeats. Below, we highlight some recent advances.
Antisense Oligonucleotide Therapy
Antisense Oligonucleotides (ASOs) are a modified single-stranded nucleic acid that can bind to mRNA targets. It functions by altering the secondary structure of mRNA, which results in blocking the binding of RBPs or triggering RNaseH-mediated degradation of target RNAs (Bennett et al., 2019). Oligonucleotide-targeting strategies have been employed successfully to improve neurodegeneration in diverse repeat disorders (Smith and Zain, 2019). One encouraging example is amyotrophic lateral sclerosis (ALS). Research showed that ASOs targeting upstream of the GGGGCC repeats led to reduction of RNA foci, increased survival from glutamate excitotoxicity, and improvement of abnormal gene expression in fibroblast and induced pluripotent stem cell (iPSC)-derived neurons (Sareen et al., 2013; Abati et al., 2020). Further studies conducted in mouse models confirmed these results: ASOs targeting the repeat-containing RNAs reduced the formation of RNA foci and toxic proteins, thus alleviating the behavioral and cognitive deficits (McCampbell et al., 2018). Similarly, a breakthrough has been made in the targeted knockdown of the CAG repeat containing RNA using a synthetic gapmer oligonucleotide in the myotonic dystrophy I mouse model (Nguyen and Yokota, 2020).
Significantly, clinical trials have been conducted in patients (Miller et al., 2013; Tabrizi et al., 2019) using ASOs targeting superoxide dismutase 1 (SOD1) in ALS and the mutant huntingtin gene in Huntington’s disease. In addition, ASO-mediated protein therapy also holds great promise. This can be achieved by reducing the protein aggregation or promoting the degradation of aberrant repeat expanded proteins. One example has been used for the ALS-associated RBP, TAR DNA-binding protein (TDP-43). ASOs were successfully used to target ataxin-2, an RBP with multiple roles in RNA metabolism. ASOs targeting ataxin-2 in TDP-43 transgenic mice could reduce aggregation of TDP-43 protein, thus extending their lifespan and improving their motor function (Becker et al., 2017). Another group also identified that ASOs targeting ataxin 2 could suppress neurodegeneration in ALS and frontotemporal dementia (FTD) mediated by a GGGGCC hexanucleotide repeat expansion in patient-derived neurons (Zhang et al., 2018). Importantly, these results raise the possibility that ASO-mediated reduction of RBPs might be helpful in CGG repeat disorders with TDP-43 proteinopathy. Consistent with this hypothesis, a study in the FXTAS Drosophila model identified TDP-43 as a suppressor of CGG repeat-induced toxicity. The authors found that TDP-43 suppresses CGG-mediated toxicity through interactions with hnRNP A2/B1, thereby preventing the alterations in RNA splicing triggered by hnRNP A2/B1 sequestration (He et al., 2014). Thus, using ASOs targeting toxic aggregation-prone RBPs to modulate aggregation and protein degradation could be of therapeutic significance for various CGG repeat diseases.
While ASOs are highly promising for the development of therapeutic strategies, some issues have to be considered. Given that the CGG repeat structure has been proposed to be critical for the complex formation with oligonucleotides (Tran et al., 2014), this highly structured repeat expansion in the 5′ UTR could affect ASO affinity, potentially leading to the inefficient accumulation of ASOs in the target tissues. Moreover, although ASOs can efficiently diffuse through the central nervous system and have high intake by neuronal cells, the blood-brain barrier (Rinaldi and Wood, 2018) may severely hinder the delivery of ASOs, raising a key issue on how to improve efficiency of delivery. Finally, further efforts are needed to ensure that ASOs operate with CGG repeats without altering translation of the downstream open reading frame.
RNA Interference (RNAi)
RNAi has also emerged as a promising approach to treat expanded repeat disorders. With RNAi, double-stranded RNA molecules bind to target mRNAs and specifically degrade mRNA and suppress protein expression (Castanotto and Rossi, 2009). MicroRNA (miRNA), small interfering RNA (siRNA) and short hairpin RNA (shRNA) have become the most common RNA molecules for RNAi.
In ALS, studies have shown that siRNA targeting the GGGGCC repeat-containing transcripts significantly reduced mutant mRNA and RNA foci formation in fibroblasts, iPSC-derived motor neurons, and in a mouse model (Hu et al., 2017; Martier et al., 2019a, b). Similarly, in Huntington’s disease, which is caused by a CAG repeat expansion in the huntingtin gene (HTT), AMT-130, an AAV-delivered miRNA that targets Htt has been applied to reduce HTT levels successfully, leading to an improvement of neuropathology. In FXTAS, accumulating evidence from RNAi studies has shown that knockdown of gypsy (Tan et al., 2012) and TBPH (He et al., 2014) can suppress the neuronal toxicity caused by CGG repeats in a Drosophila model. However, little information is available for RNAi that directly targets the CGG repeat-containing RNAs.
Taken together, targeting CGG repeat RNAs by RNAi is expected to have therapeutic benefit in CGG repeat related disorders. However, there are still many technical issues to be studied. For instance, effective delivery of synthetic siRNAs or miRNAs into specific brain regions is challenging. RNAi systems are expected to be optimized not only to cross the blood-brain barrier but also efficiently target repeat expanded RNAs. However, the risk of off-target effects and immunogenicity should also be considered (Meng and Lu, 2017). As research progresses, advances in adeno-associated virus (AAV) vector usage have contributed substantially to the treatment of a variety of neurodegenerative diseases (Castanotto and Rossi, 2009). However, introduction of the virus into patients poses additional issues.
Small Molecules
Emerging evidence has confirmed that some small molecules can regulate CGG expansion toxicity by interacting specifically with CGG repeat RNAs (Disney et al., 2012; Yang et al., 2016). They have a high affinity for CGG hairpins and can reduce the RBPs sequestration (Tran et al., 2014) by binding to the CGG repeat transcripts. Of the small molecules identified, 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4, 3-b]carbazol-2-ium, is able to bind CGG repeats in vitro, improve FXTAS-associated splicing defects, and reduce the size and number of CGG-containing protein aggregates (Disney et al., 2012). Additional small molecules have also been identified to interact with CGG repeats, such as phospholipase A2 inhibitors (Qurashi et al., 2012), naphthyridine carbamate dimer (Hagihara et al., 2012), and piperine (Verma et al., 2019).
Compared with ASOs, small molecules bear an advantage over ASOs in that they are relatively smaller in size with a better blood-brain barrier permeability than ASOs. In addition, the small molecules can bind the CGG repeat RNAs without inhibiting translation of the downstream open reading frame. Studies have been conducted for two compounds to target CGG repeats in cellular models of FXTAS. The small molecules, 2′-O-methyl phosphorothioate, could modulate CGG toxicity better than oligonucleotides carrying 2′-O-methyl phosphorothioate (Tran et al., 2014). The identification of additional small molecules that target CGG repeats can help identify novel therapies for not only FXTAS, but for other related disorders mediated by CGG repeats like NIID.
Small molecules can be expanded as a nanoprobe to detect CGG repeats in the early diagnosis of CGG repeat disorders. For example, small molecules immobilized on the surface of carboxyl-functionalized Fe3O4 magnetic nanoparticles was reported for CGG trinucleotide repeat detection (Zhu et al., 2017). Overall, the design of CGG hairpin structure-specific small molecules may be of great therapeutic and diagnosis interest, but low binding specificity could lead to higher risks of off-target effects. Potential immune responses caused by small molecules could also be a concern.
Gene Editing
First reported as a genome editor in eukaryotic cells in 2013 (Cong et al., 2013; Mali et al., 2013), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), which form the basis of the bacterial immune system, has become a powerful gene editing strategy. Cas9 is an RNA-guided DNA nuclease that cleaves the DNA at a location specified by a guide RNA. CRISPR-based therapy is a promising strategy for many genetic disorders and already being assessed in clinical trials. A study from repeat expansion disorders suggests that the repeats can be excised from DNA by CRISPR/Cas9 technology (van Agtmaal et al., 2017).
Thus far, research on CRISPR-editing for CGG repeat diseases has focused on FXS, which could provide some insight for FXTAS and NOTCH2NLC-related disorders. Important progress has been made by using CRISPR/Cas9 to edit FMR1 full mutation allele (CGG repeats >200) in FXS human iPSCs. It cleavages upstream of the CGG repeat site in FMR1, leading to the deletions of variable sizes, and finally resulting in the reactivation of FMR1 expression and the elevation of FMRP levels (Park et al., 2015; Xie et al., 2016). In addition, the authors also reported a decline in DNA methylation at the FMR1 locus in reactivated cells that produced FMRP. Inspired by this, another study used CRISPR/dCas9 to reverse the hypermethylation of CGG repeats in FXS iPSCs, and showed the reactivation of FMR1 expression and phenotypic rescue (Liu et al., 2018). The same effect by the CRISPR/dCas9 system has also been verified in FXS embryonic stem cells (ESCs; Haenfler et al., 2018). Direct CGG repeat-targeting single-guide RNA (sgRNAs) appear to work better than promoter-targeting sgRNAs. Taken together, these data demonstrate that treatment of FXS could benefit from the excision of the expanded CGG repeats using CRISPR-editing.
Although this genome editing approach has great potential for the treatment of CGG repeat disorders, concerns remain. First, off-target effects are difficult to detect, leading to potential disturbance of the genome and the risk for permanent off-target genetic alterations at the DNA level. The presence of erroneous cleavage sites could be dependent on the repeat structure, gRNA, and target sequence. To overcome these shortcomings, a new modified RNA-targeting Cas9 (RCas9) system to target and track RNA was established (Nelles et al., 2016). The application of CRISPR/RCas9 resulted in efficient elimination of toxic CUG, CAG, CCUG, and GGGGCC repeat expansion RNAs in human cells along with the reversal of disease-related molecular defects like the reduction of polyglutamine proteins, likely making it more suitable for FXTAS. Further research is needed to verify the RNA-targeting CRISPR in the CGG repeat diseases.
The second issue is the virus-mediated delivery. Adeno Associated Virus (AAV) is the most common delivery vehicle in vivo. However, the carrying capacity of AAV is limited to drive gRNAs and Cas9 expression. Finally, the modified gRNA design should be optimized. Although the strategy is promising, many issues need to be resolved before proceeding to clinical applications.
Perspectives
Recent years have seen a rise in findings on CGG/GGC repeat-related disorders. Various neurodegenerative diseases have been revealed to have the expanded CGG/GGC repeats within genes, like NIID and essential tremor. Those CGG/ GGC repeat disorders share lots of overlapping clinical and molecular phenotypes. For example, early FXTAS can resemble essential tremor to some extent. Thus, the abnormal repeat expansions may share similar underlying pathogenesis that affects multiple neurological phenotypes. Because underlying mechanisms and therapies for these NOTCH2NLC-related disorders are still poorly understood, correlates can be drawn from current research findings related to FXTAS. Moreover, these repeat-associated findings can be expanded to other microsatellite repeat expansion disorders beyond CGG/GGC repeat expansions. Several key questions in the field need to be addressed to provide clues for therapeutic approaches: (1) What are the exact mechanisms of the repeat RNAs and RAN translation that cause neuron toxicity? (2) Do the similar highly expressed CGG/GGC repeat transcripts in neurons play the same role in the pathogenesis contribution? and (3) Are there overlapping clinical features associated with the CGG/GGC expanded repeats in different diseases? Application of newly developed high-throughput technologies will facilitate the identification of the overlapping clinical features and mechanisms. This will undoubtedly provide better understanding of the repeat expansion diseases, offering new perspectives for therapeutic targets in this field.
Author Contributions
KX and YL wrote the manuscript. EA and PJ edited the manuscript. All authors contributed to the article and approved the submitted version.
Funding
We want to thank the NICHD and the National Institute of Neurological Disorders and Stroke (NINDS) for supporting our National Fragile X Center (U54NS091859 and P50HD104463) in which this work was conducted.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Abati, E., Bresolin, N., Comi, G., and Corti, S. (2020). Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS). Expert Opin. Ther. Targets 24, 295–310. doi: 10.1080/14728222.2020.1738390
Becker, L. A., Huang, B., Bieri, G., Ma, R., Knowles, D. A., Jafar-Nejad, P., et al. (2017). Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544, 367–371. doi: 10.1038/nature22038
Berry-Kravis, E., Abrams, L., Coffey, S. M., Hall, D. A., Greco, C., Gane, L. W., et al. (2007). Fragile X-associated tremor/ataxia syndrome: clinical features, genetics and testing guidelines. Mov. Disord. 22, 2018–2030, quiz 2140. doi: 10.1002/mds.21493
Bennett, C. F., Krainer, A. R., and Cleveland, D. W. (2019). Antisense oligonucleotide therapies for neurodegenerative diseases. Annu. Rev. Neurosci. 42, 385–406. doi: 10.1146/annurev-neuro-070918-050501
Boivin, M., Willemsen, R., Hukema, R. K., and Sellier, C. (2018). Potential pathogenic mechanisms underlying fragile X tremor ataxia syndrome: RAN translation and/or RNA gain-of-function? Eur. J. Med. Genet. 61, 674–679. doi: 10.1016/j.ejmg.2017.11.001
Castanotto, D., and Rossi, J. J. (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature 457, 426–433. doi: 10.1038/nature07758
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823. doi: 10.1126/science.1231143
Deng, J., Gu, M., Miao, Y., Yao, S., Zhu, M., Fang, P., et al. (2019). Long-read sequencing identified repeat expansions in the 5’UTR of the NOTCH2NLC gene from Chinese patients with neuronal intranuclear inclusion disease. J. Med. Genet. 56, 758–764. doi: 10.1136/jmedgenet-2019-106268
Disney, M. D., Liu, B., Yang, W. Y., Sellier, C., Tran, T., Charlet-Berguerand, N., et al. (2012). A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome. ACS Chem. Biol. 7, 1711–1718. doi: 10.1021/cb300135h
Dombrowski, C., Levesque, S., Morel, M. L., Rouillard, P., Morgan, K., and Rousseau, F. (2002). Premutation and intermediate-size FMR1 alleles in 10572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum. Mol. Genet. 11, 371–378. doi: 10.1093/hmg/11.4.371
Ellegren, H. (2004). Microsatellites: simple sequences with complex evolution. Nat. Rev. Genet. 5, 435–445. doi: 10.1038/nrg1348
Gelpi, E., Botta-Orfila, T., Bodi, L., Marti, S., Kovacs, G., Grau-Rivera, O., et al. (2017). Neuronal intranuclear (hyaline) inclusion disease and fragile X-associated tremor/ataxia syndrome: a morphological and molecular dilemma. Brain 140:e51. doi: 10.1093/brain/awx156
Greco, C. M., Berman, R. F., Martin, R. M., Tassone, F., Schwartz, P. H., Chang, A., et al. (2006). Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 129, 243–255. doi: 10.1093/brain/awh683
Haenfler, J. M., Skariah, G., Rodriguez, C. M., Monteiro da Rocha, A., Parent, J. M., Smith, G. D., et al. (2018). Targeted reactivation of fMR1 transcription in fragile X syndrome embryonic stem cells. Front. Mol. Neurosci. 11:282. doi: 10.3389/fnmol.2018.00282
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Jr., Moine, H., Kooy, R. F., et al. (2017). Fragile X syndrome. Nat. Rev. Dis. Primers 3:17065. doi: 10.1038/nrdp.2017.65
Hagerman, R. J., Leehey, M., Heinrichs, W., Tassone, F., Wilson, R., Hills, J., et al. (2001). Intention tremor, parkinsonism and generalized brain atrophy in male carriers of fragile X. Neurology 57, 127–130. doi: 10.1212/wnl.57.1.127
Hagihara, M., He, H., Kimura, M., and Nakatani, K. (2012). A small molecule regulates hairpin structures in d(CGG) trinucleotide repeats. Bioorg. Med. Chem. Lett. 22, 2000–2003. doi: 10.1016/j.bmcl.2012.01.030
Haltia, M., Somer, H., Palo, J., and Johnson, W. G. (1984). Neuronal intranuclear inclusion disease in identical twins. Ann. Neurol. 15, 316–321. doi: 10.1002/ana.410150403
He, F., Krans, A., Freibaum, B. D., Taylor, J. P., and Todd, P. K. (2014). TDP-43 suppresses CGG repeat-induced neurotoxicity through interactions with HnRNP A2/B1. Hum. Mol. Genet. 23, 5036–5051. doi: 10.1093/hmg/ddu216
Hu, J., Rigo, F., Prakash, T. P., and Corey, D. R. (2017). Recognition of c9orf72 mutant RNA by single-stranded silencing RNAs. Nucleic Acid Ther. 27, 87–94. doi: 10.1089/nat.2016.0655
Hukema, R. K., Buijsen, R. A., Raske, C., Severijnen, L. A., Nieuwenhuizen-Bakker, I., Minneboo, M., et al. (2014). Induced expression of expanded CGG RNA causes mitochondrial dysfunction in vivo. Cell Cycle 13, 2600–2608. doi: 10.4161/15384101.2014.943112
Hunsaker, M. R., Greco, C. M., Spath, M. A., Smits, A. P., Navarro, C. S., Tassone, F., et al. (2011). Widespread non-central nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor/ataxia syndrome and CGG knock-in mice. Acta Neuropathol. 122, 467–479. doi: 10.1007/s00401-011-0860-9
Ishiura, H., Shibata, S., Yoshimura, J., Suzuki, Y., Qu, W., Doi, K., et al. (2019). Noncoding CGG repeat expansions in neuronal intranuclear inclusion disease, oculopharyngodistal myopathy and an overlapping disease. Nat. Genet. 51, 1222–1232. doi: 10.1038/s41588-019-0458-z
Iwahashi, C. K., Yasui, D. H., An, H. J., Greco, C. M., Tassone, F., Nannen, K., et al. (2006). Protein composition of the intranuclear inclusions of FXTAS. Brain 129, 256–271. doi: 10.1093/brain/awh650
Jacquemont, S., Hagerman, R. J., Leehey, M. A., Hall, D. A., Levine, R. A., Brunberg, J. A., et al. (2004). Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 291, 460–469. doi: 10.1001/jama.291.4.460
Jiao, B., Zhou, L., Zhou, Y., Weng, L., Liao, X., Tian, Y., et al. (2020). Identification of expanded repeats in NOTCH2NLC in neurodegenerative dementias. Neurobiol. Aging 89, 142.e1–142.e7. doi: 10.1016/j.neurobiolaging.2020.01.010
Jin, P., Duan, R., Qurashi, A., Qin, Y., Tian, D., Rosser, T. C., et al. (2007). Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome. Neuron 55, 556–564. doi: 10.1016/j.neuron.2007.07.020
Jin, P., Zarnescu, D. C., Zhang, F., Pearson, C. E., Lucchesi, J. C., Moses, K., et al. (2003). RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila. Neuron 39, 739–747. doi: 10.1016/s0896-6273(03)00533-6
Kenneson, A., Zhang, F., Hagedorn, C. H., and Warren, S. T. (2001). Reduced FMRP and increased fMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum. Mol. Genet. 10, 1449–1454. doi: 10.1093/hmg/10.14.1449
La Spada, A. R., and Taylor, J. P. (2010). Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat. Rev. Genet. 11, 247–258. doi: 10.1038/nrg2748
Liu, X. S., Wu, H., Krzisch, M., Wu, X., Graef, J., Muffat, J., et al. (2018). Rescue of fragile X syndrome neurons by DNA methylation editing of the fMR1 gene. Cell 172, 979.e6–992.e6. doi: 10.1016/j.cell.2018.01.012
Lim, S. Y., Ishiura, H., Ramli, N., Shibata, S., Almansour, M. A., Tan, A. H., et al. (2020). Adult-onset neuronal intranuclear inclusion disease mimicking Fragile X-associated tremor-ataxia syndrome in ethnic Chinese patients. Parkinsonism Relat. Disord. 74, 25–27. doi: 10.1016/j.parkreldis.2020.03.025
Ma, D., Tan, Y. J., Ng, A. S. L., Ong, H. L., Sim, W., Lim, W. K., et al. (2020). Association of NOTCH2NLC repeat expansions with Parkinson disease. JAMA Neurol. 77, 1–5. doi: 10.1001/jamaneurol.2020.3023
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., et al. (2013). RNA-guided human genome engineering via Cas9. Science 339, 823–826. doi: 10.1126/science.1232033
Martier, R., Liefhebber, J. M., Garcia-Osta, A., Miniarikova, J., Cuadrado-Tejedor, M., Espelosin, M., et al. (2019a). Targeting RNA-mediated toxicity in C9orf72 ALS and/or FTD by RNAi-based gene therapy. Mol. Ther. Nucleic Acids 16, 26–37. doi: 10.1016/j.omtn.2019.02.001
Martier, R., Liefhebber, J. M., Miniarikova, J., van der Zon, T., Snapper, J., Kolder, I., et al. (2019b). Artificial MicroRNAs targeting C9orf72 can reduce accumulation of intra-nuclear transcripts in ALS and FTD patients. Mol. Ther. Nucleic Acids 14, 593–608. doi: 10.1016/j.omtn.2019.01.010
McCampbell, A., Cole, T., Wegener, A. J., Tomassy, G. S., Setnicka, A., Farley, B. J., et al. (2018). Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J. Clin. Invest. 128, 3558–3567. doi: 10.1172/JCI99081
Meng, Z., and Lu, M. (2017). RNA interference-induced innate immunity, off-target effect, or immune adjuvant? Front. Immunol. 8:331. doi: 10.1016/j.omtn.2019.01.010
Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., et al. (2013). An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 12, 435–442. doi: 10.1016/S1474-4422(13)70061-9
Mirkin, S. M. (2007). Expandable DNA repeats and human disease. Nature 447, 932–940. doi: 10.1038/nature05977
Mori, F., Tanji, K., Odagiri, S., Toyoshima, Y., Yoshida, M., Ikeda, T., et al. (2012). Ubiquilin immunoreactivity in cytoplasmic and nuclear inclusions in synucleinopathies, polyglutamine diseases and intranuclear inclusion body disease. Acta Neuropathol. 124, 149–151. doi: 10.1007/s00401-012-0999-z
Muslimov, I. A., Patel, M. V., Rose, A., and Tiedge, H. (2011). Spatial code recognition in neuronal RNA targeting: role of RNA-hnRNP A2 interactions. J. Cell Biol. 194, 441–457. doi: 10.1083/jcb.201010027
Nelles, D. A., Fang, M. Y., O’Connell, M. R., Xu, J. L., Markmiller, S. J., Doudna, J. A., et al. (2016). Programmable RNA tracking in live cells with CRISPR/Cas9. Cell 165, 488–496. doi: 10.1016/j.cell.2016.02.054
Nguyen, Q., and Yokota, T. (2020). Degradation of toxic RNA in myotonic dystrophy using gapmer antisense oligonucleotides. Methods Mol. Biol. 2176, 99–109. doi: 10.1007/978-1-0716-0771-8_7
Okubo, M., Doi, H., Fukai, R., Fujita, A., Mitsuhashi, S., Hashiguchi, S., et al. (2019). GGC repeat expansion of NOTCH2NLC in adult patients with leukoencephalopathy. Ann. Neurol. 86, 962–968. doi: 10.1002/ana.25586
Park, C. Y., Halevy, T., Lee, D. R., Sung, J. J., Lee, J. S., Yanuka, O., et al. (2015). Reversion of FMR1 methylation and silencing by editing the triplet repeats in fragile X iPSC-derived neurons. Cell Rep. 13, 234–241. doi: 10.1016/j.celrep.2015.08.084
Payseur, B. A., Jing, P., and Haasl, R. J. (2011). A genomic portrait of human microsatellite variation. Mol. Biol. Evol. 28, 303–312. doi: 10.1093/molbev/msq198
Pountney, D. L., Raftery, M. J., Chegini, F., Blumbergs, P. C., and Gai, W. P. (2008). NSF, Unc-18–1, dynamin-1 and HSP90 are inclusion body components in neuronal intranuclear inclusion disease identified by anti-SUMO-1-immunocapture. Acta Neuropathol. 116, 603–614. doi: 10.1007/s00401-008-0437-4
Qurashi, A., Liu, H., Ray, L., Nelson, D. L., Duan, R., and Jin, P. (2012). Chemical screen reveals small molecules suppressing fragile X premutation rCGG repeat-mediated neurodegeneration in Drosophila. Hum. Mol. Genet. 21, 2068–2075. doi: 10.1093/hmg/dds024
Richard, G. F., Kerrest, A., and Dujon, B. (2008). Comparative genomics and molecular dynamics of DNA repeats in eukaryotes. Microbiol. Mol. Biol. Rev. 72, 686–727. doi: 10.1128/MMBR.00011-08
Rinaldi, C., and Wood, M. J. A. (2018). Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat. Rev. Neurol. 14, 9–21. doi: 10.1038/nrneurol.2017.148
Sareen, D., O’Rourke, J. G., Meera, P., Muhammad, A. K., Grant, S., Simpkinson, M., et al. (2013). Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 5:208ra149. doi: 10.1126/scitranslmed.3007529
Sellier, C., Buijsen, R. A. M., He, F., Natla, S., Jung, L., Tropel, P., et al. (2017). Translation of expanded CGG repeats into FMRpolyG is pathogenic and may contribute to fragile X tremor ataxia syndrome. Neuron 93, 331–347. doi: 10.1016/j.neuron.2016.12.016
Sellier, C., Freyermuth, F., Tabet, R., Tran, T., He, F., Ruffenach, F., et al. (2013). Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep. 3, 869–880. doi: 10.1016/j.celrep.2013.02.004
Sellier, C., Rau, F., Liu, Y., Tassone, F., Hukema, R. K., Gattoni, R., et al. (2010). Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J. 29, 1248–1261. doi: 10.1038/emboj.2010.21
Smith, C. I. E., and Zain, R. (2019). Therapeutic oligonucleotides: state of the art. Annu. Rev. Pharmacol. Toxicol. 59, 605–630. doi: 10.1146/annurev-pharmtox-010818-021050
Sofola, O. A., Jin, P., Qin, Y., Duan, R., Liu, H., de Haro, M., et al. (2007). RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 55, 565–571. doi: 10.1016/j.neuron.2007.07.021
Sone, J., Mitsuhashi, S., Fujita, A., Mizuguchi, T., Hamanaka, K., Mori, K., et al. (2019). Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease. Nat. Genet. 51, 1215–1221. doi: 10.1038/s41588-019-0459-y
Sone, J., Mori, K., Inagaki, T., Katsumata, R., Takagi, S., Yokoi, S., et al. (2016). Clinicopathological features of adult-onset neuronal intranuclear inclusion disease. Brain 139, 3170–3186. doi: 10.1093/brain/aww249
Sone, J., Tanaka, F., Koike, H., Inukai, A., Katsuno, M., Yoshida, M., et al. (2011). Skin biopsy is useful for the antemortem diagnosis of neuronal intranuclear inclusion disease. Neurology 76, 1372–1376. doi: 10.1212/WNL.0b013e3182166e13
Sun, Q. Y., Xu, Q., Tian, Y., Hu, Z. M., Qin, L. X., Yang, J. X., et al. (2020). Expansion of GGC repeat in the human-specific NOTCH2NLC gene is associated with essential tremor. Brain 143, 222–233. doi: 10.1093/brain/awz372
Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., et al. (2019). Targeting huntingtin expression in patients with Huntington’s disease. N. Engl. J. Med. 380, 2307–2316. doi: 10.1056/NEJMoa1900907
Tan, H., Qurashi, A., Poidevin, M., Nelson, D. L., Li, H., and Jin, P. (2012). Retrotransposon activation contributes to fragile X premutation rCGG-mediated neurodegeneration. Hum. Mol. Genet. 21, 57–65. doi: 10.1093/hmg/ddr437
Tian, Y., Wang, J. L., Huang, W., Zeng, S., Jiao, B., Liu, Z., et al. (2019). Expansion of human-specific GGC repeat in neuronal intranuclear inclusion disease-related disorders. Am. J. Hum. Genet. 105, 166–176. doi: 10.1016/j.ajhg.2019.05.013
Todd, P. K., Oh, S. Y., Krans, A., He, F., Sellier, C., Frazer, M., et al. (2013). CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron 78, 440–455. doi: 10.1016/j.neuron.2013.03.026
Todd, P. K., and Paulson, H. L. (2010). RNA-mediated neurodegeneration in repeat expansion disorders. Ann. Neurol. 67, 291–300. doi: 10.1002/ana.21948
Toth, G., Gaspari, Z., and Jurka, J. (2000). Microsatellites in different eukaryotic genomes: survey and analysis. Genome Res. 10, 967–981. doi: 10.1101/gr.10.7.967
Tran, T., Childs-Disney, J. L., Liu, B., Guan, L., Rzuczek, S., and Disney, M. D. (2014). Targeting the r(CGG) repeats that cause FXTAS with modularly assembled small molecules and oligonucleotides. ACS Chem. Biol. 9, 904–912. doi: 10.1021/cb400875u
van Agtmaal, E. L., Andre, L. M., Willemse, M., Cumming, S. A., van Kessel, I. D. G., van den Broek, W., et al. (2017). CRISPR/Cas9-induced (CTGCAG) repeat instability in the myotonic dystrophy type 1 locus: implications for therapeutic genome editing. Mol. Ther. 25, 24–43. doi: 10.1016/j.ymthe.2016.10.014
Verma, A. K., Khan, E., Mishra, S. K., Jain, N., and Kumar, A. (2019). Piperine modulates protein mediated toxicity in fragile X-associated tremor/ataxia syndrome through interacting expanded CGG repeat r(CGG)exp RNA. ACS Chem. Neurosci. 10, 3778–3788. doi: 10.1021/acschemneuro.9b00282
Williams, A. J., and Paulson, H. L. (2008). Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci. 31, 521–528. doi: 10.1016/j.tins.2008.07.004
Xie, N., Gong, H., Suhl, J. A., Chopra, P., Wang, T., and Warren, S. T. (2016). Reactivation of FMR1 by CRISPR/Cas9-mediated deletion of the expanded CGG-repeat of the fragile X chromosome. PLoS One 11:e0165499. doi: 10.1371/journal.pone.0165499
Yang, W. Y., He, F., Strack, R. L., Oh, S. Y., Frazer, M., Jaffrey, S. R., et al. (2016). Small molecule recognition and tools to study modulation of r(CGG)exp in fragile X-associated tremor ataxia syndrome. ACS Chem. Biol. 11, 2456–2465. doi: 10.1021/acschembio.6b00147
Zhang, N., and Ashizawa, T. (2017). RNA toxicity and foci formation in microsatellite expansion diseases. Curr. Opin. Genet. Dev. 44, 17–29. doi: 10.1016/j.gde.2017.01.005
Zhang, K., Daigle, J. G., Cunningham, K. M., Coyne, A. N., Ruan, K., Grima, J. C., et al. (2018). Stress granule assembly disrupts nucleocytoplasmic transport. Cell 173, 958–971. doi: 10.1016/j.cell.2018.03.025
Zu, T., Gibbens, B., Doty, N. S., Gomes-Pereira, M., Huguet, A., Stone, M. D., et al. (2011). Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl. Acad. Sci. U S A 108, 260–265. doi: 10.1073/pnas.1013343108
Keywords: FXTAS, NIID, ET, RNA dysregulation, sequestration, RNA binding proteins, miRNA, therapeutic strategies
Citation: Xu K, Li Y, Allen EG and Jin P (2021) Therapeutic Development for CGG Repeat Expansion-Associated Neurodegeneration. Front. Cell. Neurosci. 15:655568. doi: 10.3389/fncel.2021.655568
Received: 19 January 2021; Accepted: 12 April 2021;
Published: 12 May 2021.
Edited by:
Guey-Shin Wang, Academia Sinica, TaiwanReviewed by:
Muge Kuyumcu-Martinez, University of Texas Medical Branch at Galveston, United StatesBarbara Bardoni, UMR7275 Institut de pharmacologie moléculaire et cellulaire (IPMC), France
Copyright © 2021 Xu, Li, Allen and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Peng Jin, peng.jin@emory.edu